-
Cybin Moves Forward With Phase 1/2a Clinical Trial For Treatment Of Major Depressive Disorder
Friday, June 10, 2022 - 5:34pm | 337Read More...Cybin Inc. (NEO: CYBN), the biopharma company ‘focused on progressing Psychedelics to Therapeutics’ by creating safe and effective therapeutics for patients to address various mental health disorders, has received Institutional Review Board approval to launch the first-in-human Phase 1/...
